Suggested Readings

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.

Fleischmann R, et al. Lancet. 2017;390(10093):457-468.

Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials.

Strand V, et al. Arthritis Res Ther. 2015;17:362.

Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis.

Clowse MEB, et al. Drug Saf. 2016;39(8):755-762.

Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis.

Pérez-Baos S, et al. Br J Pharmacol. 2017;174(18):3018-3031.

Baricitinib versus placebo or adalimumab in rheumatoid arthritis.

Taylor PC, et al. N Engl J Med. 2017;376(7):652-662.

Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease‐modifying antirheumatic drug treatment.

Fleischmann R, et al. Arthritis Rheumatol. 2017;69(3):506-517.

Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 8.4 years: an updated integrated safety analysis.

Genovese MC, et al. Ann Rheum Dis. 2020;79(suppl 10):642-643. Abstract FRI0123.

Upadacitinib monotherapy in methotrexate-naïve patients with rheumatoid arthritis: results at 72 weeks from SELECT-EARLY.

van Vollenhoven R, et al. Ann Rheum Dis. 2020;79(suppl 1):333-335. Abstract THU0217.

Long-term safety and effectiveness of upadacitinib or adalimumab in patients with rheumatoid arthritis: results at 72 weeks from the SELECT-COMPARE study.

Fleischmann R, et al. Ann Rheum Dis. 2020;79(suppl 1):323. Abstract THU0201.

Efficacy and safety of upadacitinib versus abatacept in patients with active rheumatoid arthritis and prior inadequate response or intolerance to biologic disease-modifying anti-rheumatic drugs (SELECT-CHOICE): a double-blind, randomized controlled phase 3 trial.

Rubbert-Roth A, et al. Ann Rheum Dis. 2020;79(suppl 1):1015-1016. Abstract SAT0151.

Safety profile of upadacitinib up to 3 years of exposure in patients with rheumatoid arthritis.

Cohen SB, et al. Ann Rheum Dis. 2020;79(suppl 1):319-320. Abstract THU0197.

Efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate: FINCH 1 52-week results.

Combe B, et al. Ann Rheum Dis. 2020;79(suppl 1):320-321. Abstract THU0198.

Efficacy and safety of filgotinib in methotrexate-naïve patients with rheumatoid arthritis: FINCH 3 52-week results.

Westhovens R, et al. Ann Rheum Dis. 2020;79(suppl 1):1019-1020. Abstract SAT0158.

Integrated safety analysis of filgotinib treatment for rheumatoid arthritis from 7 clinical trials.

Genovese MC, et al. Ann Rheum Dis. 2020;79(suppl 1):324-325. Abstract THU0202.

Clinical efficacy of new JAK inhibitors under development. Just more of the same?

Westhovens R. Rheumatology (Oxford). 2019;58(suppl 1):i27-i33.

Efficacy and safety of switching Jakinibs in rheumatoid arthritis.

Retuerto-Guerrero M, et al. Ann Rheum Dis. 2020;79(suppl 1):648-649. Abstract FRI0132.

Thromboembolic safety reporting of tofacitinib and baricitinib: an analysis of the WHO VigiBase.

Vallejo-Yagüe E, et al. Drug Saf. 2020;43(9):881-891.

Janus Kinase Inhibitors for Rheumatoid Arthritis: Effectiveness and Value.

Institute for Clinical and Economic Review. October 11, 2019.

The Impact of Step-Therapy Policies on Patients

Snow J, et al. Xcenda AmerisourceBergen. December 4, 2019.

Treatment delays associated with prior authorization for infusible medications: a cohort study.

Wallace ZS, et al. Arthritis Care Res (Hoboken). 2019. [Epub ahead of print.]

Additional abstracts from EULAR 2020 E-Congress.

Additional abstracts from EULAR 2020 E-Congress. From June 3, 2020.

Clinician, Patient, and Caregiver Resources

Coalition of State Rheumatology Association (CSRO) Legislative Map Tool

The CSRO’s legislative map tool provides information about existing and pending step therapy, nonmedical switching, accumulator adjustment program, and uniform prior authorization laws by state and at the federal level.

American College of Rheumatology: Patient and Caregiver Resources

The ACR has produced a library of videos about the impact of rheumatic disease, what to do when diagnosed with rheumatic disease, when to see a rheumatologist, and what patients have to say about their experiences of living with rheumatic disease.

Arthritis Foundation

The Arthritis Foundation provides self-care tools and resources covering treatment options, pain management, diet and exercise, and common comorbidities associated with many different arthritic conditions.

European League Against Rheumatism

EULAR is an organization that represents people with arthritis/rheumatism, health professionals, and scientific societies of rheumatology of all the European nations.

NIH Health Topics: Rheumatoid Arthritis

A resource from the National Institute of Arthritis and Musculoskeletal and Skin Diseases for people who have rheumatoid arthritis, as well as for their family members, friends, and others who want to find out more about rheumatoid arthritis.